Related Experiment Video

Updated: Apr 13, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

Anti-PD-L1 for metastatic triple-negative breast cancer

Josefine Gibson

    The Lancet. Oncology
    |May 5, 2015
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    1.3K
    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
    10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.8K

    Related Experiment Videos

    Last Updated: Apr 13, 2026

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
    07:43

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

    Published on: September 25, 2018

    11.2K
    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    1.3K
    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
    10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.8K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    9.2K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K

    Articles linked to this work by shared authors, journal, and citation graph.

    IL-27 inhibits lymphatic endothelial cell proliferation by STAT1-regulated gene expression.

    Microcirculation (New York, N.Y. : 1994)·2013

    IL-20 activates human lymphatic endothelial cells causing cell signalling and tube formation.

    Microvascular research·2009

    Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

    The Lancet. Oncology·2026

    Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

    The Lancet. Oncology·2026

    Advancing oncology education in low-income and middle-income African settings: global insights for local action.

    The Lancet. Oncology·2026

    Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

    The Lancet. Oncology·2026

    Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

    The Lancet. Oncology·2026

    Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

    The Lancet. Oncology·2026

    Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

    Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

    Roles of TIR domain-containing adaptor protein in tumor: Inflammation and immune regulation via toll-like receptor signaling.

    The Journal of international medical research·2026

    Design, Synthesis, and Evaluation of Alkoxyamine Anticancer Prodrugs Bearing Galactoside as an Enzyme-Activated Trigger.

    Chemical research in toxicology·2026

    The Dual Role of DNA Cross-linking Agents: From Genotoxicity to cGAS-STING-Mediated Immune Activation.

    Chemical research in toxicology·2026

    High-Resolution Mass Spectrometric Analysis of Selected DNA Adducts in Smokeless Tobacco Users' Oral Cells.

    Chemical research in toxicology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us